MCID: SBR001
MIFTS: 30

Seborrheic Infantile Dermatitis

Categories: Skin diseases

Aliases & Classifications for Seborrheic Infantile Dermatitis

MalaCards integrated aliases for Seborrheic Infantile Dermatitis:

Name: Seborrheic Infantile Dermatitis 12 15 17
Seborrhoea Capitis 12 32
Cradle Cap 12 70
Generalized Seborrheic Dermatitis of Infants 12
Complement Component 5 Deficiency 70
Infantile Seborrhoeic Dermatitis 12
Infantile Seborrheic Dermatitis 12
Seborrhoeic Dermatitis of Scalp 12
Seborrheic Dermatitis of Scalp 70
Seborrhoeic Eczema of Scalp 12
Complement 5 Dysfunction 12
Seborrheic Dermatitis 70
Scurfiness of Scalp 70
Pityriasis Capitis 12
Seborrhea Capitis 12
Seborrhea Sicca 12
Dandruff 44

Classifications:



External Ids:

Disease Ontology 12 DOID:8941
ICD9CM 34 690.11
MeSH 44 D063807
SNOMED-CT 67 48596006
ICD10 32 L21.0 L21.1
UMLS 70 C0036508 C0221244 C0263233 more

Summaries for Seborrheic Infantile Dermatitis

Disease Ontology : 12 A seborrheic dermatitis that involves fungal infection of the scalp of recently born babies caused by Malassezia furfur. It is occasionally linked to immune disorders. The symptoms include thick, crusty, yellow or brown scales over the child's scalp.

MalaCards based summary : Seborrheic Infantile Dermatitis, also known as seborrhoea capitis, is related to seborrheic dermatitis and dermatitis, atopic. An important gene associated with Seborrheic Infantile Dermatitis is RPL39L (Ribosomal Protein L39 Like), and among its related pathways/superpathways are Cytokine Signaling in Immune system and IL-17 Family Signaling Pathways. The drugs Isotretinoin and Clotrimazole have been mentioned in the context of this disorder. Affiliated tissues include skin and breast.

Related Diseases for Seborrheic Infantile Dermatitis

Diseases in the Seborrheic Dermatitis family:

Seborrheic Infantile Dermatitis

Diseases related to Seborrheic Infantile Dermatitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 35)
# Related Disease Score Top Affiliating Genes
1 seborrheic dermatitis 11.3
2 dermatitis, atopic 10.4
3 dermatitis 10.2
4 skin disease 10.2
5 pyoderma 10.1
6 acne 10.1
7 alopecia 10.1
8 superficial mycosis 10.1
9 ige responsiveness, atopic 10.0
10 herpes simplex 10.0
11 eczema herpeticum 10.0
12 exanthem 10.0
13 tinea pedis 10.0
14 scalp dermatosis 10.0
15 tinea capitis 10.0
16 dermatophytosis 10.0
17 pityriasis versicolor 10.0
18 blepharitis 10.0
19 papillomatosis, confluent and reticulated 9.8
20 asthma 9.8
21 suppressor of tumorigenicity 11 9.8
22 androgenic alopecia 9.8
23 diffuse alopecia areata 9.8
24 allergic disease 9.8
25 fungal infectious disease 9.8
26 telogen effluvium 9.8
27 contact dermatitis 9.8
28 breast adenocarcinoma 9.8
29 hair disease 9.8
30 pustulosis of palm and sole 9.8
31 folliculitis 9.8
32 psoriasis 9.8
33 demodicidosis 9.8
34 cutaneous candidiasis 9.6 IL17RE IL17RC
35 chronic mucocutaneous candidiasis 9.3 IL17RE IL17RC IL17RB

Comorbidity relations with Seborrheic Infantile Dermatitis via Phenotypic Disease Network (PDN):


Acute Cystitis

Graphical network of the top 20 diseases related to Seborrheic Infantile Dermatitis:



Diseases related to Seborrheic Infantile Dermatitis

Symptoms & Phenotypes for Seborrheic Infantile Dermatitis

Drugs & Therapeutics for Seborrheic Infantile Dermatitis

Drugs for Seborrheic Infantile Dermatitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 63)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Isotretinoin Approved Phase 4 4759-48-2 5538 5282379
2
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
3
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
4
Petrolatum Approved, Investigational Phase 4 8009-03-8
5
Ketoconazole Approved, Investigational Phase 4 65277-42-1 47576
6
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
7
Calcitriol Approved, Nutraceutical Phase 4 32222-06-3 134070 5280453
8 Salicylates Phase 4
9 Cyclooxygenase Inhibitors Phase 4
10 Keratolytic Agents Phase 4
11 Antifungal Agents Phase 4
12 Anti-Infective Agents Phase 4
13 Dermatologic Agents Phase 4
14 Immunosuppressive Agents Phase 4
15 Calcineurin Inhibitors Phase 4
16 Emollients Phase 4
17 Cytochrome P-450 CYP3A Inhibitors Phase 4
18 Hormone Antagonists Phase 4
19 Hormones Phase 4
20 Cytochrome P-450 Enzyme Inhibitors Phase 4
21 Calcium, Dietary Phase 4
22 Vasoconstrictor Agents Phase 4
23 Anti-Inflammatory Agents Phase 4
24
Calcium Nutraceutical Phase 4 7440-70-2 271
25
Pimecrolimus Approved, Investigational Phase 2, Phase 3 137071-32-0 6447131 17753757
26
Ciclopirox Approved, Investigational Phase 3 29342-05-0 2749
27
Clobetasol Approved, Experimental, Investigational Phase 3 25122-46-7, 25122-41-2 32798 5311051
28 Antirheumatic Agents Phase 2, Phase 3
29 Analgesics Phase 2, Phase 3
30 Anti-Inflammatory Agents, Non-Steroidal Phase 2, Phase 3
31 Analgesics, Non-Narcotic Phase 2, Phase 3
32 Sunscreening Agents Phase 2, Phase 3
33 glucocorticoids Phase 3
34
Ichthammol Approved Phase 2 8029-68-3
35
Azelaic acid Approved Phase 2 123-99-9 2266
36
Acetylcholine Approved, Investigational Phase 1 51-84-3 187
37 Cholinergic Agents Phase 1
38 Neurotransmitter Agents Phase 1
39 Botulinum Toxins Phase 1
40
Hydrocortisone Approved, Vet_approved 50-23-7 5754
41
Hydrocortisone acetate Approved, Vet_approved 50-03-3
42
Aminolevulinic acid Approved 106-60-5 137
43
Salicylic acid Approved, Investigational, Vet_approved 69-72-7 338
44
Selenium Approved, Investigational, Vet_approved 7782-49-2
45
Ethanol Approved 64-17-5 702
46
Iodine Approved, Investigational 7553-56-2 807
47
Vitamin D Approved, Nutraceutical, Vet_approved 1406-16-2
48
Cadexomer iodine Experimental 94820-09-4
49 Hydrocortisone 17-butyrate 21-propionate
50 Hydrocortisone hemisuccinate

Interventional clinical trials:

(show all 33)
# Name Status NCT ID Phase Drugs
1 Clinical, Laboratorial and Quality of Life Trial to Evaluate the Efficacy and Safety of Low-dose Oral Isotretinoin for Seborrhea. Unknown status NCT01139749 Phase 4 oral isotretinoin;salicylic acid and ciclopirox olamine
2 A Double Blind, Placebo-Controlled, Pilot Study to Estimate the Efficacy and Tolerability of Twice Daily Promiseb Topical Cream in Pediatric Subjects With Cradle Cap (Seborrheic Dermatitis) Completed NCT01214434 Phase 4
3 A PHASE 4, OPEN-LABEL STUDY TO ASSESS THE LONG-TERM SAFETY OF EXTINA (KETOCONAZOLE) FOAM, 2% IN THE TREATMENT OF SEBORRHEIC DERMATITIS Completed NCT00703846 Phase 4 Ketoconazole
4 Phase 4 Study of Proactive Treatment of Tacrolimus Ointment for Adult Facial Seborrheic Dermatitis Completed NCT01591070 Phase 4 Tacrolimus;Tacrolimus
5 A Double Blind Randomized Trial, Placebo-controled of 0.0003% Calcitriol Ointment Versus 0.1% Tacrolimus Ointment in the Treatment of Pityriasis Alba Completed NCT01388517 Phase 4 Tacrolimus;Calcitriol;Petrolatum
6 A Proof of Concept Clinical Trial Evaluating the Safety and Efficacy of Eucrisa (Crisaborole) in Patients With Seborrheic Dermatitis Recruiting NCT03567980 Phase 4 Crisaborole
7 Efficacy of Topical Pimecrolimus in the Treatment of Pityriasis Alba: A Randomized Placebo-controlled Trial Unknown status NCT03834935 Phase 2, Phase 3 Elidel (pimecrolimus 1%);Cold Cream
8 A Multicenter, Randomised, Double Blind, Placebo-controlled Study of Efficacy, Safety, and Tolerability of Kaprolac® K301 for the Treatment of Seborrhoeic Eczema (SE) of the Scalp Completed NCT01137331 Phase 3 K301;Placebo
9 Efficacy and Safety of Clobetasol Propionate Shampoo 0.05% Used in Association With an Antifungal Shampoo in the Treatment of Moderate to Severe Scalp Seborrheic Dermatitis Completed NCT00862654 Phase 3 clobetasol propionate shampoo (4/week) - ketoconazole shampoo (2/week);clobetasol propionate shampoo (2/week) - ketoconazole shampoo (2/week);clobetasol propionate shampoo (2/week);ketoconazole shampoo (2/week)
10 Phase 3 : Tacrolimus Ointment Interest (PROTOPIC ®) in the Maintenance Treatment of Severe Seborrheic Dermatitis on Adult Face Completed NCT02004860 Phase 3 Protopic (R);Mycoster (R)
11 Efficacy and Safety of ASF 1057 Cream 0.5% in the Treatment of Seborrhoeic Dermatitis: A Phase III Randomised, Double-Blind, Vehicle and Placebo Controlled, Parallel Groups, Multi-Centre Trial. Completed NCT00565279 Phase 3 ASF1057;ASF1057
12 A Phase 2, Randomized, Vehicle and Ketoconazole-Controlled, Evaluator-Blinded, Study to Explore the Efficacy, Pharmacodynamics and Safety of Omiganan 1.75% Topical Gel BID in Patients With Mild to Moderate Facial Seborrheic Dermatitis Unknown status NCT03688971 Phase 2 Omiganan;Ketoconazole;Placebo
13 The Role of Topically Dissolved Oxygen (TDO) to Ameliorate Signs of Photodamage in Individuals With Multiple Skin Conditions A Double-Blind, Placebo Controlled Comparative Trial Completed NCT00991198 Phase 2 Topical oxygen;Topical oxygen;placebo
14 A 4 Week Randomized Double-Blind Parallel Group Active Comparator Controlled Study of Elidel for the Treatment of Seborrheic Dermatitis Completed NCT00403559 Phase 2 Elidel
15 The Efficacy of Sodium Shale Oil Sulponate 1% Shampoo in the Treatment of Pityriasis Capitis Completed NCT02448082 Phase 2
16 A Randomized, Double-blind, Single Center, Investigator-initiated Clinical Study to Evaluate the Safety and Efficacy of PAC-14028 Cream in Subjects With Mild to Moderate Seborrheic Dermatitis of the Face Completed NCT02749383 Phase 2 PAC-14028 cream 0.3%;PAC-14028 cream 1.0%;PAC-14028 cream vehicle
17 A Parallel-group, Vehicle-controlled, Randomized, Double-blind Study of the Efficacy and Safety of Product 49778 and Product 10156 in Subjects With Seborrheic Dermatitis Completed NCT01703793 Phase 2 Test Product 49778;Test Product 10156;Vehicle (placebo)
18 A Phase 2b, 8-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-154 Foam 0.3% Administered QD in Subjects With Seborrheic Dermatitis Completed NCT04091646 Phase 2 ARQ-154 foam 0.3%
19 A Double-Blind, Randomized, Vehicle-Controlled, Six-Week Exploratory Multicenter Pilot Study of the Efficacy and Safety of Azelaic Acid (AzA) 15% Gel in the Topical Treatment of Mild to Moderate Seborrheic Dermatitis of the Face Completed NCT00408330 Phase 2 Azelaic Acid 15% Gel;Inactive 15% gel base
20 A Phase 2, Multicenter, Open-Label Study of the Long-Term Safety of ARQ-154 Foam 0.3% in Subjects With Seborrheic Dermatitis Recruiting NCT04445987 Phase 2 ARQ-154
21 Botulinum Toxin for Treatment of Seborrhic Dermatitis in Parkinsonian Patients Unknown status NCT00767546 Phase 1 Botulinum toxin
22 Petrolatum's Effect on Initial Symptoms of Nonscalp Seborrheic Dermatitis and Preventing Exacerbation Unknown status NCT01315951
23 Avaliação da eficácia de um Produto de Uso tópico Contendo Hidrocortisona no Tratamento de Dermatite seborréica na Face. Unknown status NCT01024374
24 An Open-Label Study of the HairMax LaserComb(r) in the Treatment of Seborrheic Dermatitis of the Scalp. Completed NCT00830908
25 Neurobiology of the Scalp in Seborrheic Dermatitis Completed NCT02349854
26 Safety and Efficacy of SEBORRHEAMEDIS Face Cream in Patients With Seborrheic Dermatitis Completed NCT02656368
27 Seborrheic Dermatitis of the Scalp in Populations Practicing Less Frequent Hair Washing: Ketoconazole 2% Foam Versus Ketoconazole 2% Shampoo Completed NCT01203189 ketoconazole 2% foam;ketoconazole 2% shampoo
28 Comparison of Scalp Microbiota of the Patients With Psoriasis Vulgaris and Seborrheic Dermatitis Completed NCT03807453
29 Pilot Study for the Use of Photodynamic Therapy in the Treatment of Seborrheic Dermatitis Completed NCT03114111 aminolevulinic acid (ALA);Placebo
30 Using the SpiderMass(TM) for in Vivo and Real Time Mass Spectrometry Analysis of Subject's Epidermis Suffering From Chronic Inflammatory Dermatosis Compared to Control Groups Recruiting NCT04472546
31 Multicentric, Randomized, Double Blind Study Under Dermatological Control for Evaluation of the Antidandruff Maintenance Effect of One Shampoo (Reference 1144628 D) Versus Its Vehicle (Reference 1144781) During 8 Weeks After a Ketoconazole-based Antifungal Treatment During 4 Weeks in Adult Subjects (Male and Female) With Light to Moderate Seborrheic Dermatitis Recruiting NCT04057950
32 Serum 25(OH) Vitamin D and Total Serum Immunoglobulin E Levels in Patients With Pityriasis Alba Active, not recruiting NCT03443765
33 Prospective Clinical Observation of Ventriculo-peritoneal Shunt in Patients With Hydrocephalus and Application of "Three-step Disinfection" in Reducing the Incidence of Post-operative Infection: a Multicenter Randomized Controlled Study Not yet recruiting NCT04785248

Search NIH Clinical Center for Seborrheic Infantile Dermatitis

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Betamethasone
Betamethasone acetate
Betamethasone benzoate
betamethasone dipropionate
betamethasone sodium phosphate
Betamethasone valerate
BETAMETHASONE VALERATE PWDR
chloroxine
Coal Tar
Coal tar extract
Coal tar pitch volatiles
COAL TAR,COLLOIDAL
COAL TAR,REFINED
Colloid sulfur
Ketoconazole
Salicylic Acid
SALICYLIC ACID PWDR
selenium sulfide
Sulfacetamide
Sulfacetamide Sodium
Sulfur
SULFUR PWDR
SULFUR,COLLOIDAL
zinc pyrithione

Cochrane evidence based reviews: dandruff

Genetic Tests for Seborrheic Infantile Dermatitis

Anatomical Context for Seborrheic Infantile Dermatitis

MalaCards organs/tissues related to Seborrheic Infantile Dermatitis:

40
Skin, Breast

Publications for Seborrheic Infantile Dermatitis

Articles related to Seborrheic Infantile Dermatitis:

# Title Authors PMID Year
1
A school survey of tinea capitis in Benghazi, Libya. 61
469980 1979
2
The treatment of refractory seborrhoea capitis. (Long-term results with hiphenamine hydrochloride). 61
14467054 1962
3
A cetrimide preparation for seborrhoea capitis and seborrhoeic dermatitis. 61
13453100 1957
4
Seborrhoea capitis infantum. 61
13337414 1956

Variations for Seborrheic Infantile Dermatitis

Expression for Seborrheic Infantile Dermatitis

Search GEO for disease gene expression data for Seborrheic Infantile Dermatitis.

Pathways for Seborrheic Infantile Dermatitis

Pathways related to Seborrheic Infantile Dermatitis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.37 IL17RE IL17RD IL17RC IL17RB
2
Show member pathways
11.26 IL17RE IL17RD IL17RC IL17RB

GO Terms for Seborrheic Infantile Dermatitis

Biological processes related to Seborrheic Infantile Dermatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine-mediated signaling pathway GO:0019221 9.26 IL17RE IL17RD IL17RC IL17RB
2 interleukin-17-mediated signaling pathway GO:0097400 8.8 IL17RE IL17RC IL17RB

Molecular functions related to Seborrheic Infantile Dermatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 interleukin-17 receptor activity GO:0030368 8.92 IL17RE IL17RD IL17RC IL17RB

Sources for Seborrheic Infantile Dermatitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....